Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".
Clewell
Jerry D
JD
Baker
Robert W
RW
D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000191:economics / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D008390:Markov Chains; D000077152:Olanzapine; D017063:Outcome Assessment, Health Care; D010349:Patient Compliance; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000191:economics; D018967:Risperidone / Q000191:economics / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine